Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 5:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 742 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Migraine Headache Clear all
Completed Not applicable Interventional

MigraineManager: An Individualized Self-Management Tool for Adolescents With Migraine

NCT03157739
View directory record Official record
Conditions
Migraine Disorders
Interventions
MigraineManager: Individualized Self-Management Tool
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
11 Years to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 25, 2026, 5:44 AM EDT
Completed Phase 3 Interventional Results available

TREXIMET (Formerly Known as TREXIMA) for the Acute Treatment of Probable Migraine (ICHD-II 1.6.1)

NCT00387881
View directory record Official record
Conditions
Migraine, Without Aura
Interventions
sumatriptan succinate / naproxen sodium, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
679 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
70
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 58 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 25, 2026, 5:44 AM EDT
Terminated No phase listed Observational

Frovatriptan and Menstrual Migraine

NCT01114711
View directory record Official record
Conditions
Frovatriptan, Menstrual Migraine
Interventions
Not listed
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 12, 2018 · Synced Oct 25, 2026, 5:44 AM EDT
Not listed Not applicable Interventional

Unwinding Anxiety for Migraine: Pilot

NCT06150612
View directory record Official record
Conditions
Migraine, Anxiousness
Interventions
Unwinding Anxiety
Behavioral
Lead sponsor
Yeshiva University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Dec 8, 2023 · Synced Oct 25, 2026, 5:44 AM EDT
Terminated Not applicable Interventional Results available

Timolol Eye Drops in the Treatment of Acute Migraine Headache

NCT02630719
View directory record Official record
Conditions
Migraine
Interventions
Timolol eye drops, Artificial tears
Drug
Lead sponsor
University of Missouri, Kansas City
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated May 15, 2019 · Synced Oct 25, 2026, 5:44 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety and Efficacy of ZP-Zolmitriptan Intracutaneous Microneedle Systems for the Acute Treatment of Migraine

NCT02745392
View directory record Official record
Conditions
Acute Migraine
Interventions
ZP-Zolmitriptan, Placebo
Drug
Lead sponsor
Zosano Pharma Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
36
States / cities
Glendale, Arizona • Carlsbad, California • Huntington Beach, California + 32 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Oct 25, 2026, 5:44 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Headache Ear Auditory Dizziness Sinus (HEADS) Registry

NCT07754266
View directory record Official record
Conditions
Headache Disorders, Dizziness, Vestibular Diseases, Sinus Disease, Vestibular Disorder, Migraine Disorders, Headache, Migraine, Facial Pain
Interventions
Not listed
Lead sponsor
Association of Migraine Disorders
Other
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2033
U.S. locations
1
States / cities
North Kingstown, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 25, 2026, 5:44 AM EDT
Completed Phase 2 Interventional

Study to Evaluate the Efficacy and Safety of Dronabinol Metered Dose Inhaler (MDI) in Acute Treatment of Migraine Headache

NCT00123201
View directory record Official record
Conditions
Migraine With Aura, Migraine Without Aura
Interventions
Dronabinol MDI
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
29
States / cities
Huntsville, Alabama • Tucson, Arizona • Anaheim, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2015 · Synced Oct 25, 2026, 5:44 AM EDT
Completed Phase 2 Interventional

Efficacy of Inhaled Cannabis for Acute Migraine Treatment

NCT04360044
View directory record Official record
Conditions
Migraine, Cannabis, THC, CBD
Interventions
THC ~5%, CBD ~12%, THC ~5% and CBD ~12%, Sham Cannabis
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
21 Years to 65 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Oct 25, 2026, 5:44 AM EDT
Terminated Not applicable Interventional

Understanding the Pathophysiology of Migraine Pain

NCT03026101
View directory record Official record
Conditions
Migraine Disorders, Migraine, Classic, Migraine Without Aura
Interventions
Nitroglycerin
Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 20, 2025 · Synced Oct 25, 2026, 5:44 AM EDT
Completed Phase 4 Interventional Results available

Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine

NCT05264129
View directory record Official record
Conditions
Episodic Migraine
Interventions
Atogepant, Ubrogepant
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 80 Years
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
37
States / cities
Birmingham, Alabama • Phoenix, Arizona • Oceanside, California + 34 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 25, 2026, 5:44 AM EDT
Completed Phase 3 Interventional

A Study of Rizatriptan Co-Administered With Acetaminophen for the Treatment of Acute Migraine

NCT00300924
View directory record Official record
Conditions
Migraine
Interventions
Rizatriptan co-administered with Acetaminophen
Drug
Lead sponsor
Diamond Headache Clinic
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
7
States / cities
San Francisco, California • Chicago, Illinois • Kalamazoo, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated May 28, 2008 · Synced Oct 25, 2026, 5:44 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Migraine and CVD Risk in Women

NCT03081390
View directory record Official record
Conditions
Migraine
Interventions
Mixed meal tolerance testing, Skin conductance & cold pressor test, Flow-mediated dilation testing
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2026
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 25, 2026, 5:44 AM EDT
Recruiting No phase listed Observational

Puberty, Testosterone, and Brain Development

NCT06670053
View directory record Official record
Conditions
Gender Identity, Gender Dysphoria in Adolescents and Adults, Headache, Transgender
Interventions
Testosterone
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 20 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 25, 2026, 5:44 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Chronic Pain Risk Associated With Menstrual Period Pain

NCT02214550
View directory record Official record
Conditions
Cystitis, Interstitial, Dysmenorrhea, Migraine Disorders, Pelvic Pain, Endometriosis, Visceral Pain, Chronic Pain
Interventions
cyclic microgestin 1/20, continuous microgestin 1/20
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
353 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2021
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 25, 2026, 5:44 AM EDT
Completed Not applicable Interventional Results available

Cooling to Alleviate Migraine #3

NCT06874361
View directory record Official record
Conditions
Migraine With or Without Aura, Migraine, Migraine Headache
Interventions
Mi-Helper
Device
Lead sponsor
Mi-Helper, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Indian Harbour Beach, Florida
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 25, 2026, 5:44 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study of Intramuscular Ropivacaine Injections for Treatment of Pediatric Headache

NCT00680823
View directory record Official record
Conditions
Headache, Migraine
Interventions
Ropivacaine, Normal saline
Drug
Lead sponsor
Robert Hickey
Other
Eligibility
7 Years to 17 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 26, 2018 · Synced Oct 25, 2026, 5:44 AM EDT
Not yet recruiting Phase 3 Interventional

0.5% Bupivacaine Lower Cervical Intramuscular Injection vs IV Medications for Headache Treatment

NCT06937385
View directory record Official record
Conditions
Headache, Migraine, Tension Headache, Occipital Neuralgia
Interventions
0.5% Bupivacaine HCl, standard IV treatment for headache
Drug
Lead sponsor
HCA Florida North Florida Hospital
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Oct 25, 2026, 5:44 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention

NCT02456740
View directory record Official record
Conditions
Migraine
Interventions
Erenumab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
955 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
59
States / cities
Phoenix, Arizona • Anaheim, California • Encino, California + 55 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Oct 25, 2026, 5:44 AM EDT
Completed Not applicable Interventional

Intensive Meditation and Migraines: Effects on Health and Well Being

NCT00663585
View directory record Official record
Conditions
Chronic Daily Headache
Interventions
Vipassana Meditation
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 29, 2016 · Synced Oct 25, 2026, 5:44 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Adolescents With Migraine: What's Stress Got To Do With It?

NCT02259387
View directory record Official record
Conditions
Headache, Migraine
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
13 Years to 17 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 8, 2018 · Synced Oct 25, 2026, 5:44 AM EDT
Recruiting No phase listed Observational

Emgality for Migraine in Breastmilk

NCT06085144
View directory record Official record
Conditions
Migraine
Interventions
Galcanezumab
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 25, 2026, 5:44 AM EDT
Terminated Phase 4 Interventional

Tandem OnabotulinumtoxinA Galcanezumab Emerging Therapeutic Headache Elimination Research Study

NCT05492695
View directory record Official record
Conditions
Migraine
Interventions
Galcanezumab, Placebo
Drug · Other
Lead sponsor
Diamond Headache Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 29, 2023 · Synced Oct 25, 2026, 5:44 AM EDT
Recruiting Phase 2 Interventional

Clinical Trial of Endoscopically Guided Injection of Exparel (Bupivacaine) for the Treatment of Craniofacial Pain

NCT04930887
View directory record Official record
Conditions
Craniofacial Pain, Migraine, Cluster Headache, Trigeminal Autonomic Cephalgia, Sphenopalatine Ganglion Neuralgia, Paroxysmal Hemicrania
Interventions
Exparel (Bupivacaine Liposome), Saline
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 25, 2026, 5:44 AM EDT